Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $190.00 short put and a strike $180.00 long put offers a potential 22.85% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $190.00 by expiration. The full premium credit of $1.86 would be kept by the premium seller. The risk of $8.14 would be incurred if the stock dropped below the $180.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients
Thu, 20 May 2021 13:26:41 +0000
Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased cardiovascular risk. Measuring the GLP-1 receptor agonist tirzepatide against titrated insulin glargine, Lilly reported that its program hit all primary and key secondary endpoints across three dosage levels. The primary endpoint was measured at 52 weeks, and many participants continued treatment beyond 52 weeks, some up to two years. It’s the fifth Phase 3 study Lilly has completed for the candidate, and now it plans to submit details to regulatory authorities later in 2021. Participants began the study with an average baseline A1C of 8.52%, and each of the treatment arms lowered the levels at a significant rate compared to titrated insulin glargine, Lilly said. At one year, the changes for each escalating dose were -2.24%, -2.43% and -2.58%, against -1.44% for the control. Tirzepatide reduced weight from the average baseline by 8.1%, 10.7%, and 13% for the three arms, respectively. Meanwhile, participants in the titrated insulin glargine arm saw a mean weight increase of 2.2% relative to the baseline. Lilly noted that the overall safety results in the study were consistent with the profile of the GLP-1 class, with gastrointestinal side effects proving to be the most common such as nausea, diarrhea, and vomiting. Price Action: LLY shares closed at $196.5 on Wednesday. See more from BenzingaClick here for options trades from BenzingaLilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDALilly, MiNA Ink Broad RNA Deal Worth .25B© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
Thu, 20 May 2021 10:45:00 +0000
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular (CV) risk compared to titrated insulin glargine in topline results from Eli Lilly and Company's (NYSE: LLY) SURPASS-4 clinical trial. For the efficacy estimandi, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (25.8 lb., 13.0 percent) compared to results for those treated with insulin glargine (A1C reduction of 1.44 percent and weight gain of 1.9 kg [4.2 lb., 2.2 percent]) at 52 weeks.
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Wed, 19 May 2021 21:00:00 +0000
New data from across Eli Lilly and Company's (NYSE: LLY) oncology portfolio will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 4-8, 2021. The data include new analyses of Verzenio® (abemaciclib) from the Phase 3 monarchE trial in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) with a high risk of recurrence who received neoadjuvant chemotherapy. In addition, the first clinical data from the Phase 1 study of Lilly's oral selective estrogen receptor degrader (SERD) will be presented at the meeting.
New Strong Sell Stocks for May 19th
Wed, 19 May 2021 13:14:01 +0000
ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC
Tue, 18 May 2021 14:12:02 +0000
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
Also on Market Tamer…
Follow Us on Facebook